Telix Pharmaceuticals

Telix Pharmaceuticals Liabilities

The The Liabilities of Telix Pharmaceuticals (TLX.AX) as of Nov 20, 2026 is 748.61 M USD. In the previous year, The Liabilities was 587.44 M USD — a change of 27.44% (higher).

Liabilities

748.61 MUSD

YoY

27.44%

Last updated:

In 2025, Telix Pharmaceuticals's total liabilities amounted to 748.61 M USD, a 27.44% difference from the 587.44 M USD total liabilities in the previous year.

The Telix Pharmaceuticals Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
23.80 M USD
Jan 1, 2019
32.53 M USD
Jan 1, 2020
78.81 M USD
Jan 1, 2021
107.66 M USD
Jan 1, 2022
113.71 M USD
Jan 1, 2023
174.61 M USD
Jan 1, 2024
587.44 M USD
Jan 1, 2025
748.61 M USD
The Telix Pharmaceuticals Liabilities history
YEARLiabilitiesYoY
748.61 MUSD+27.44%
587.44 MUSD+236.43%
174.61 MUSD+53.56%
113.71 MUSD+5.63%
107.66 MUSD+36.61%
78.81 MUSD+142.28%
32.53 MUSD+36.65%
23.80 MUSD+1,221.77%
1.80 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Telix Pharmaceuticals's Liabilities

Telix Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Telix Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Telix Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Telix Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Telix Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Telix Pharmaceuticals stock

The Liabilities of Telix Pharmaceuticals is 748.61 M USD in 2025.

The Liabilities of Telix Pharmaceuticals changed from 587.44 M USD to 748.61 M USD, representing a 27.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals